Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Kris · SciRah

Researcher profile · Semantic Scholar

M. Kris

Share profile

M. Kris — researcher profile on SciRah

h-index: 148
Works: 912
Citations: 99K

Most-cited papers

Evolution of systemic therapy for stages I–III non-metastatic non-small cell lung cancer
J. Chaft, A. Rimner, W. Weder, C. Azzoli +2 more
2021Nature Reviews Clinical Oncology333 citations Open access
Semantic Scholar
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
J. Chaft, F. Oezkan, M. Kris, P. Bunn +32 more
2022Nature Medicine233 citations Open access
Semantic Scholar
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
J. Jee, E. Lebow, R. Yeh, J. Das +68 more
2022Nature Medicine159 citations Open access
Semantic Scholar
Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-mediated Apoptosis
Kosuke Tanaka, H. Yu, Shao-Hui Yang, Song Han +16 more
2021Cancer Cell142 citations Open access
Semantic Scholar
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis
Jonathan T. Yang, N. Wijetunga, E. Pentsova, S. Wolden +18 more
2022Journal of Clinical Oncology105 citations Open access
Semantic Scholar
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer
K. Arbour, H. Rizvi, A. Plodkowski, M. Hellmann +9 more
2021Clinical Cancer Research105 citations Open access
Semantic Scholar
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
N. Choudhury, A. Marra, J. Sui, J. Flynn +15 more
2022Journal of Thoracic Oncology104 citations Open access
Semantic Scholar
Beyond steroids: immunosuppressants in steroid-refractory/resistant immune related adverse events
Jia Luo, J. Beattie, P. Fuentes, H. Rizvi +9 more
2021Journal of Thoracic Oncology100 citations Open access
Semantic Scholar
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
J. Lee, C. Mcnamee, E. Toloza, M. Negrao +10 more
2023Journal of Thoracic Oncology79 citations Open access
Semantic Scholar
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
K. Pisters, M. Kris, L. Gaspar, Nofisat Ismaila
2022Journal of Clinical Oncology74 citations Open access
Semantic Scholar
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
Ju-Whei Lee, J. Chaft, A. Nicholas, A. Patterson +26 more
202171 citations Open access
Semantic Scholar
Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions
N. Choudhury, A. Schoenfeld, J. Flynn, C. Falcon +8 more
2021Clinical Cancer Research57 citations Open access
Semantic Scholar
Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer
Anup K Biswas, S. Han, Yi-Fan Tai, Wan-Chao Ma +19 more
2022Cancer Discovery56 citations Open access
Semantic Scholar
Deciphering radiological stable disease to immune checkpoint inhibitors
J. Luo, S. Wu, H. Rizvi, Q. Zhang +15 more
2022Annals of Oncology46 citations Open access
Semantic Scholar
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
S. Dacic, W. Travis, M. Redman, A. Saqi +38 more
2023Journal of Thoracic Oncology44 citations Open access
Semantic Scholar
Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell free DNA over cell pellet genomic DNA for molecular profiling.
T. Bale, Soo-Ryum Yang, James P. Solomon, K. Nafa +21 more
2021Journal of Molecular Diagnostics44 citations Open access
Semantic Scholar
Deep Learning of Cell Spatial Organizations Identifies Clinically Relevant Insights in Tissue Images
Shidan Wang, Ruichen Rong, Dong-Han M. Yang, Xinyi Zhang +9 more
2023Research Square41 citations Open access
Semantic Scholar
OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
D. Carbone, Ju-Whei Lee, M. Kris, I. Wistuba +27 more
202139 citations Open access
Semantic Scholar
Brief Report: Molecular characterization of peritoneal mesotheliomas
M. Offin, Soo-Ryum Yang, J. Egger, G. Jayakumaran +9 more
2021Journal of Thoracic Oncology33 citations Open access
Semantic Scholar
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
S. Mukherjee, C. Bandlamudi, M. Hellmann, Y. Kemel +33 more
2022Cancer Epidemiology, Biomarkers and Prevention32 citations Open access
Semantic Scholar
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
V. Rusch, A. Nicholas, G. Patterson, Salama N. Waqar +25 more
2022Journal of Thoracic and Cardiovascular Surgery30 citations Open access
Semantic Scholar
The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study
M. Zauderer, Axel Martin, J. Egger, H. Rizvi +8 more
2021The Lancet Digital Health29 citations Open access
Semantic Scholar
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
R. Thummalapalli, B. Ricciuti, C. Bandlamudi, Daniel M Muldoon +24 more
2023Clinical Cancer Research28 citations Open access
Semantic Scholar
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis
N. Wijetunga, A. Boire, R. Young, Y. Yamada +10 more
2021Neuro-Oncology Advances26 citations Open access
Semantic Scholar
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy
E. Lebow, N. Shaverdian, J. Eichholz, L. Kratochvil +28 more
2023Frontiers in Oncology25 citations Open access
Semantic Scholar
Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
S. Dacic, W. Travis, J. Giltnane, Filip Kos +24 more
2023Journal of Thoracic Oncology25 citations
Semantic Scholar
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers
M. Gutierrez, R. Guo, G. Giaccone, Stephen V. Liu +6 more
2021Lung Cancer24 citations Open access
Semantic Scholar
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
Y. Murciano-Goroff, T. Pak, S. Mondaca, J. Flynn +20 more
2021British Journal of Cancer22 citations Open access
Semantic Scholar
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis
Jonathan T. Yang, D. Yerramilli, E. Pentsova, S. Wolden +20 more
2025JAMA Oncology21 citations Open access
Semantic Scholar
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
P. Paik, Jia Luo, Nikolenko Ai, R. Kim +11 more
2022Nature Communications20 citations Open access
Semantic Scholar
A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.
H. Yu, Monica F. Chen, Angela B. Hui, N. Choudhury +16 more
2024Journal of Clinical Oncology16 citations
Semantic Scholar
Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.
S. Dacic, W. Travis, J. Giltnane, J. Abel +16 more
202116 citations
Semantic Scholar
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases
J. Wilcox, M. Jeng, S. Tischfield, Jane Sui +10 more
2025Annals of Oncology15 citations Open access
Semantic Scholar
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer
Shidan Wang, Ruichen Rong, Dong-Han M. Yang, J. Fujimoto +16 more
2023Journal of Clinical Investigation15 citations Open access
Semantic Scholar
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
A. Elkrief, B. Ricciuti, J. Alessi, Teng Fei +17 more
2023The Oncologist15 citations Open access
Semantic Scholar
LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.
B. Sepesi, David R. Jones, B. Meyers, J. Chaft +14 more
2022Journal of Clinical Oncology15 citations
Semantic Scholar
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
Jia Luo, A. Makhnin, Y. Tobi, Linda S Ahn +7 more
2021JCO Precision Oncology15 citations Open access
Semantic Scholar
Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors.
Monica F. Chen, Soo-Ryum Yang, J. Shia, J. Girshman +6 more
2023JCO Precision Oncology14 citations Open access
Semantic Scholar
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer
J. Neal, D. Costa, A. Muzikansky, J. Shrager +10 more
2021JCO Precision Oncology14 citations Open access
Semantic Scholar
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib
N. Choudhury, A. Makhnin, Y. Tobi, R. Daly +8 more
2021JCO Precision Oncology14 citations Open access
Semantic Scholar
Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets
Monica F. Chen, Soo-Ryum Yang, Jessica J Tao, Antoine Desilets +19 more
2024Clinical Cancer Research12 citations Open access
Semantic Scholar
Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.
K. Arbour, B. Ricciuti, H. Rizvi, M. Hellmann +8 more
202112 citations
Semantic Scholar
Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.
Monica F. Chen, Swanand Rakhade, Á. Quintanal-Villalonga, J. Lee +10 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
A. Elkrief, J. Alessi, B. Ricciuti, Samantha Brown +17 more
2023Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
P. Paik, R. Kim, Linda S Ahn, A. Plodkowski +11 more
2020Clinical Cancer Research11 citations Open access
Semantic Scholar
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
Monica F. Chen, J. Lee, Noura J. Choudhury, Angela B. Hui +21 more
2025Journal of Thoracic Oncology10 citations Open access
Semantic Scholar
Global advances and future directions in lung cancer care: expert consensus and strategic priorities
May-Lucie Meyer, S. Peters, P. Jänne, Tony S. K. Mok +55 more
2026ESMO Open9 citations Open access
Semantic Scholar
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Da-Zhi Liu, V. Makker, Darren J. Buonocore, R. Shen +16 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
K. Arbour, E. Manchado, M. Bott, Linda S Ahn +15 more
2021JTO Clinical and Research Reports9 citations Open access
Semantic Scholar
Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images
Shidan Wang, Ruichen Rong, Qin Zhou, Donghan M. Yang +11 more
2023Nature Communications8 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Gregory Riely×17
Invite
Gregory Riely — researcher profile on SciRah
C. Rudin×17
Invite
C. Rudin — researcher profile on SciRah
J. Chaft×15
Invite
J. Chaft — researcher profile on SciRah
H. Yu×14
Invite
H. Yu — researcher profile on SciRah

×13

Invite

M. Ladanyi — researcher profile on SciRah

M. Hellmann×10

Invite

M. Hellmann — researcher profile on SciRah

Invite

H. Rizvi — researcher profile on SciRah

Invite

I. Wistuba — researcher profile on SciRah

Invite

V. Rusch — researcher profile on SciRah

Invite

M. Arcila — researcher profile on SciRah

Invite

Linda S Ahn — researcher profile on SciRah

Invite

M. Offin — researcher profile on SciRah